Here we list selected publications covering Epimune's technology and products. For a comprehensive publication overview please see downloadable .pdf at the bottom of this page.

  • Epigenetic Immune Cell Counting to Analyze Potential Biomarkers in Preterm Infants: A Proof of Principle in Necrotizing Enterocolitis (Schoenaker et al., 2023).

  • FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome (Wyatt et al., 2022).
  • Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation (Narula M et al., 2022).
  • Future Perspectives of Newborn Screening for Inborn Errors of Immunity (Blom et al., 2022).

  • Second Tier Testing to Reduce the Number of Non-actionable Secondary Findings and False-Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency (Blom et al., 2022).
  • Epigenetic immune cell counting in human blood samples for immunodiagnostics (Baron et al., 2018).


For posters and presentations please see:

Comprehensive list of publications describing epigenetic immune cell quantification and its applications:

Publication List Epigenetic Immune Cell Quantification (DEC 2021)
Epimune Publications_DEC 2021.pdf
Adobe Acrobat Document 184.2 KB